Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Pierson

Showing results (271-280 of 322) with videos related to

Pageof 33
Sort By:
The Journal of Infectious Diseases|January 15, 2008
A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trialJulie E Martin, Theodore C Pierson, Sarah Hubka, et al.
The Lancet. Microbe|February 15, 2025
Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: an open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled studyMelinda J Hamer, James M McCarty, Benjamin C Pierson, et al.
American Journal of Human Genetics|April 24, 2012
PSORS2 is due to mutations in CARD14Catherine T Jordan, Li Cao, Elisha D O Roberson, et al.
Lancet (London, England)|August 19, 2014
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trialLee-Jah Chang, Kimberly A Dowd, Floreliz H Mendoza, et al.
Journal of Environmental Management|October 2, 2018
How practitioners integrate decision triggers with existing metrics in conservation monitoringClaire N Foster, Luke S O'Loughlin, Chloe F Sato, et al.
Cell Host & Microbe|October 5, 2021
Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunityRita E Chen, Brittany K Smith, John M Errico, et al.
Vaccines|August 28, 2025
Systemic and Mucosal Humoral Immune Responses to Lumazine Synthase 60-mer Nanoparticle SARS-CoV-2 VaccinesCheng Cheng, Jeffrey C Boyington, Edward K Sarfo, et al.
Nature Communications|September 24, 2017
A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damageChao Shan, Antonio E Muruato, Brett W Jagger, et al.
Biorxiv : the Preprint Server for Biology|September 18, 2025
Protective immunity against malaria by a nanoparticle CIS43-based junctional vaccine alone or in combination with R21Prabhanshu Tripathi, Ja-Hyun Koo, Xuejun Chen, et al.
The Pharmacogenomics Journal|September 9, 2023
The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trialMichael T Eadon, Marc B Rosenman, Pengyue Zhang, et al.
Pageof 33

Showing results (271-280 of 322) with videos related to

Sort By:
Pageof 33
The Journal of Infectious Diseases|January 15, 2008
A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trialJulie E Martin, Theodore C Pierson, Sarah Hubka, et al.
The Lancet. Microbe|February 15, 2025
Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: an open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled studyMelinda J Hamer, James M McCarty, Benjamin C Pierson, et al.
American Journal of Human Genetics|April 24, 2012
PSORS2 is due to mutations in CARD14Catherine T Jordan, Li Cao, Elisha D O Roberson, et al.
Lancet (London, England)|August 19, 2014
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trialLee-Jah Chang, Kimberly A Dowd, Floreliz H Mendoza, et al.
Journal of Environmental Management|October 2, 2018
How practitioners integrate decision triggers with existing metrics in conservation monitoringClaire N Foster, Luke S O'Loughlin, Chloe F Sato, et al.
Cell Host & Microbe|October 5, 2021
Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunityRita E Chen, Brittany K Smith, John M Errico, et al.
Vaccines|August 28, 2025
Systemic and Mucosal Humoral Immune Responses to Lumazine Synthase 60-mer Nanoparticle SARS-CoV-2 VaccinesCheng Cheng, Jeffrey C Boyington, Edward K Sarfo, et al.
Nature Communications|September 24, 2017
A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damageChao Shan, Antonio E Muruato, Brett W Jagger, et al.
Biorxiv : the Preprint Server for Biology|September 18, 2025
Protective immunity against malaria by a nanoparticle CIS43-based junctional vaccine alone or in combination with R21Prabhanshu Tripathi, Ja-Hyun Koo, Xuejun Chen, et al.
The Pharmacogenomics Journal|September 9, 2023
The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trialMichael T Eadon, Marc B Rosenman, Pengyue Zhang, et al.
Pageof 33